Table 3.
Results of sensitivity analyses (median, mean, and range)
| Indicator | Median (best estimate) | Mean | 95% Certainty interval |
|---|---|---|---|
| Share (s) of patients experiencing persistent symptoms after tE (20 days) | 0.3383 | 0.3379 | 0.2684–0.4084 |
| DALYs from persistent symptoms | 0.0192 | 0.0481 | 0.0080–0.0825 |
| Overall duration of persistent symptoms | 0.0865 | 0.2240 | 0.0401–0.3590 |
| DALYs per episode (acute phase only)* | |||
| Ambulatory episode | 0.0107 | 0.0108 | 0.0057–0.0151 |
| Hospitalized episode | 0.0152 | 0.0153 | 0.0100–0.0201 |
| Overall | 0.0115 | 0.0116 | 0.0058–0.0185 |
| Overall DALYs per episode† | |||
| Ambulatory episode | 0.0307 | 0.0588 | 0.0170–0.0917 |
| Hospitalized episode | 0.0351 | 0.0632 | 0.0241–0.0960 |
| Overall | 0.0315 | 0.0596 | 0.0178–0.0925 |
DALYs = disability-adjusted life years.
*
Summing onset and recovery periods.
†
Summing acute (onset and recovery periods) and persistent symptoms phases. All estimates are for nonfatal cases only.